Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can rapid IV fluids outpace standard care for a Life-Threatening salt imbalance?

NCT ID NCT07783191

Disease control Sponsor: Columbia University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 24, 2026 · Last updated Aug 25, 2026 · Updated 1 time

Summary

This trial tests whether giving fluids more quickly than usual can safely correct severe hypernatremia, a dangerous condition where sodium levels in the blood are too high. Researchers will compare rapid rehydration against standard care in 80 adults with sodium levels of 155 mEq/L or higher. The goal is to see if this approach is feasible and to gather early data on safety and effectiveness, which could inform a larger study on survival outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Intravenous Dextrose 5% solution (D5W), a sterile glucose and water solution used for rapid rehydration
What this could lead to
If rapid rehydration proves safe and effective, it could become a standard approach to treat severe hypernatremia, potentially reducing complications and improving survival.
What could go wrong
This is a small phase 2 feasibility trial, so results may not be definitive. Rapid sodium correction carries risks, including neurological complications, and the approach may not be safe for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

May 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 21 years or older * In the ED/medical wards/MICU * Na ≥ 155mEq/L at consent. Exclusion Criteria: * Weight \< 40 kg or \> 120 kg * Unresolved hypotension: Two or more measurements of SBP \< 90mmHg or MAP \< 65mmHg, or any use of inotropes at the time eligibility is being assessed * Fingerstick or serum glucose \> 500mg/dL at the time eligibility is being assessed * Diabetic ketoacidosis * Diabetes insipidus * Acute or chronic need for dialysis, or unresolved urinary obstruction * Recent (30 days) cerebrovascular accident, clinical seizures, evidence of CNS mass, herniation, midline shift or vasogenic edema, or any CNS invasive procedure * Recent (30 days) of acute coronary syndrome, congestive heart failure exacerbation, arrhythmia, or invasive cardiac procedure, not including diagnostic cardiac catheterization without intervention * Women who are pregnant or breastfeeding * Patients receiving only comfort care measures * Previously enrolled in this trial * Legally authorized representative unable to consent in English or Spanish

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypernatremia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hypernatremia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypernatremia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Columbia University Irving Medical Center / New-York Presbyterian

    New York, New York, 10032, United States